Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UG22
UPID:
GIMA2_HUMAN
Alternative names:
Immunity-associated protein 2
Alternative UPACC:
Q9UG22; Q96L25
Background:
GTPase IMAP family member 2, also known as Immunity-associated protein 2, is a unique protein that exhibits GTPase activity only when it forms a heterodimer with GIMAP7. This characteristic highlights its potential regulatory role in cellular processes, where its activity is modulated through interaction with other proteins.
Therapeutic significance:
Understanding the role of GTPase IMAP family member 2 could open doors to potential therapeutic strategies. Its involvement in cellular processes through GTPase activity, especially in the context of its heterodimer formation, makes it an intriguing target for drug discovery efforts aimed at modulating its function for therapeutic benefits.